Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: Subgroup analysis of a retrospective chart review study Retina

BMC Ophthalmology

Volumn 15, Issue 1, 2015, Pages

  Singer, Michael A ^a   Capone, Antonio ^b   Dugel, Pravin U ^c   Dreyer, Richard F ^d   Dodwell, David G ^e   Roth, Daniel B ^f   Shi, Rui ^g   Walt, John G ^g   Scott, Lanita C ^g   Hollander, David A ^g  

^a Medical Center Ophthalmology Associates   (United States)

^b ASSOCIATED RETINAL CONSULTANTS   (United States)

^c RETINAL CONSULTANTS OF ARIZONA   (United States)

^d Retina Northwest   (United States)

^e Illinois Retina Center   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g ALLERGAN INC   (United States)

Author keywords

Anti VEGF; Corticosteroid; Dexamethasone; Implant; Intraocular pressure; Retinal vein occlusion; Steroid

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ADMINISTRATION AND DOSAGE; AGED; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG IMPLANT; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDY; TIME FACTOR; VISUAL ACUITY;

AGED; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84926624157     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/s12886-015-0018-y     Document Type: Article

References (28)

1. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33:111-31.
2. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007;114:507-19, 524.
3. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-82.
4. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-28.
5. Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-46.e3.
6. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-12.e1.
7. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-14. Erratum in: Arch Ophthalmol. 2009;127:1648.
8. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124-33.e1.
9. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024-32. Erratum in: Ophthalmology. 2012;119:2204.
10. Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, et al. Management of retinal vein occlusion - consensus document. Ophthalmologica. 2011;226:4-28.
11. Daien V, Navarre S, Fesler P, Vergely L, Villain M, Schneider C. Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol. 2012;22:1013-8.
12. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology. 2012;119:1190-8.
13. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80-6.
14. Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453-60.
15. Capone Jr A, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, et al. Efficacy and safety of two or more dexamethasone intravitrial implant injections for the treatment of macular edema related to retinal vein occulsion (SHASTA study). Retina. 2014;34:342-51.
16. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, et al. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica. 2013;229:21-5.
17. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, et al. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97:1040-4.
18. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266-72.
19. Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG, et al. Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol. 2012;6:343-63.
20. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol. 2012;23:105-10.
21. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111-4.
22. Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250:1435-40.
23. Singh RS, Kim JE. Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. Drugs Aging. 2012;29:949-56.
24. Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging. 2012;43:328-34.
25. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012;21:241-7.
26. Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58:291-310.
27. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009;2:58.
28. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011;129:914-20.